Study of peritoneal fluid markers for fibrosis
Part of Digestive system clinical trials.
This trial looks at fluid from the belly during dialysis to find early signs of scarring (fibrosis). It includes people on peritoneal dialysis, those on hemodialysis waiting for a kidney transplant, and people with normal kidneys having hernia repair.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are on peritoneal dialysis for at least 3 months, or on hemodialysis for at least 3 months and planning a kidney transplant, or have normal kidney function and need hernia repair surgery.
- You are willing to sign a consent form.
- You have not had peritonitis in the last 3 months (if on peritoneal dialysis).
- You have no history of abdominal tumors that spread to the belly lining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new computer tool that helps doctors see how well peritoneal dialysis (a type of kidney treatment done at home) removes waste from your body. It may help make your dialysis more effective.
This study collects samples from the belly (related to the peritoneal lining) to build a “biobank” for future research. It may help patients and families by improving understanding of kidney disease and kidney dialysis-related health issues.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
Hear when a new Peritoneal Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.